Page last updated: 2024-12-10

nsc 629243

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

NSC 629243: structure given in first source; an anti-HIV drug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3000477
CHEMBL ID440510
SCHEMBL ID9198195
MeSH IDM0221694

Synonyms (29)

Synonym
nsc-629243
NCI60_009486
isopropyl 2-chloro-5-(isopropoxycarbothioylamino)benzoate
4-chloro-3-(isopropoxycarbonyl)phenylcarbamothioic acid, o-isopropyl ester
uc 38
135812-34-9
uc-38
uc38
nsc629243
UC3 ,
1-methyl ethyl 2-chloro-5-[[[(1-methylethoxy)thiooxo]methyl]amino]-benzoate
nsc 629243
DB08681
CHEMBL440510
benzoic acid, 2-chloro-5-(((1-methylethoxy)thioxomethyl)amino)-, 1-methylethyl ester
nsc-d 629243
uniroyl jr
uniroyal jr
uniroyal jr.
ccris 9414
1-methylethyl 2-chloro-5-(((1-methylethoxy)thioxomethyl)amino)benzoate
1-methylethyl 2-chloro-5-[[(1-methylethyloxy)thioxo-methyl]amino]benzoate
1-methylethyl 2-chloro-5-[[(1-methylethoxy)thioxomethyl]amino]benzoate
AXTNFJKQZPETJA-UHFFFAOYSA-N
SCHEMBL9198195
DTXSID00159542
1-methylethyl 2-chloro-5-{[(1-methylethoxy)carbonothioyl]amino}benzoate
Q27097870
isopropyl 2-chloro-5-((isopropoxycarbonothioyl)amino)benzoate

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The favorable physical characteristics, lack of toxicity, potency and bioavailability of UC 38 may make it a candidate for combination chemotherapy of acquired immune deficiency syndrome."( Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
Bader, JP; Boyd, MR; Brouwer, WG; Buckheit, RW; Currens, MJ; Felauer, EE; Gulakowski, RJ; McMahon, JB; Narayanan, VL; Russell, JD; Schultz, RJ; Shoemaker, RH; Stinson, SF; Vistica, DT, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Activity0.02900.00091.30738.0000AID199980
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID199980Inhibitory activity against human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT)2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
AID248354Concentration required to inhibit 50% viral production of human immunodeficiency virus type 1 (HIV-1-IIIB)2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (77.78)18.2507
2000's2 (22.22)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]